Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexpramipexole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 5/20 | 0.97 |
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 0.97 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | HRH2 | P25021 | 2/20 | 0.97 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.97 |
| ▸ | HTR1A | P08908 | 1/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | HTR1B | P28222 | 1/20 | 0.97 |
| ▸ | HTR2A | P28223 | 1/20 | 0.97 |
| ▸ | HTR7 | P34969 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | HRH1 | P35367 | 1/20 | 0.97 |
| ▸ | HTR2B | P41595 | 1/20 | 0.97 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.97 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.97 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.55 |
| ▸ | SCN4A | P35499 | 4/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pramipexole SCHEMBL939869 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL4099920 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL42113 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL408536 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL2995942 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL4440257 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL28716749 | 1.00 | ADRA2A (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL743891 | 0.99 | DRD3 (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL2048695 | 0.99 | DRD3 (1.00) | ADRA2ADRD3DRD2DRD4HRH2 | |
| Pramipexole SCHEMBL7106169 | 0.99 | ADRA2A (0.97) | ADRA2ADRD3DRD2DRD4HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295604-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY | 2025-09-25 | — | — | US | disclosed |
| EP-4577229-A1 | BRAIN PENETRATING PEPTIDES AND METHODS OF USE THEREOF | University of Tartu (EE) | 2025-07-02 | — | — | EP | disclosed |
| US-20250195672-A1 | DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTICS TO NEURONS | THE JOHNS HOPKINS UNIVERSITY | 2025-06-19 | — | — | US | disclosed |
| EP-4558173-A1 | DENDRIMER-ENABLED TARGETED INTRACELLULAR CRISPR/CAS SYSTEM DELIVERY AND GENE EDITING | The Johns Hopkins University (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250135012-A1 | DENDRIMER CONJUGATES OF SMALL MOLECULE BIOLOGICS FOR INTRACELLULAR DELIVERY | THE JOHNS HOPKINS UNIVERSITY | 2025-05-01 | — | — | US | disclosed |
| EP-4504268-A1 | DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTICS TO NEURONS | The Johns Hopkins University (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20250025448-A1 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | OVID THERAPEUTICS INC. | 2025-01-23 | — | — | US | disclosed |
| CN-119053344-A | Dendrimer compositions for targeted delivery of therapeutic agents to neurons | 约翰霍普金斯大学 | 2024-11-29 | — | — | CN | disclosed |
| EP-4404972-A1 | DENDRIMER CONJUGATES OF SMALL MOLECULE BIOLOGICS FOR INTRACELLULAR DELIVERY | The Johns Hopkins University (US) | 2024-07-31 | — | — | EP | disclosed |
| CN-118043076-A | Dendrimer conjugates of small molecule biologicals for intracellular delivery | 约翰霍普金斯大学 | 2024-05-14 | — | — | CN | disclosed |
| US-20130079526-A1 | Synthesis of Chirally Purified Substituted Benzothiazole Diamines | KNOPP NEUROSCIENCES INC. (US) | 2013-03-28 | — | — | US | disclosed |
| EP-2542541-A1 | SYNTHESIS OF CHIRALLY PURIFIED SUBSTITUTED BENZOTHIAZOLE DIAMINES | KNOPP NEUROSCIENCES (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120253047-A1 | PROCESS FOR THE PREPARATION OF (R)-PRAMIPEXOLE | DIPHARMA S.P.A. (IT) | 2012-10-04 | — | — | US | disclosed |
| EP-2442655-A1 | COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Knopp Neurosciences, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2011109596-A1 | SYNTHESIS OF CHIRALLY PURIFIED SUBSTITUTED BENZOTHIAZOLE DIAMINES | KNOPP NEUROSCIENCES (US) | 2011-09-09 | — | — | WO | disclosed |
| US-20110009460-A1 | COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KNOPP BIOSCIENCES LLC | 2011-01-13 | — | — | US | disclosed |
| WO-2010148409-A1 | COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KNOPP NEUROSCIENCES, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| EP-2137171-A2 | SYNTHESIS OF CHIRALLY PURIFIED SUBSTITUTED BENZOTHIAZOLE DIAMINES | Knopp Neurosciences, Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008113056-A2 | SYNTHESIS OF CHIRALLY PURIFIED SUBSTITUTED BENZOTHIAZOLE DIAMINES | KNOPP NEUROSCIENCES, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227985-A1 | SYNTHESIS OF CHIRALLY PURIFIED SUBSTITUTED BENZOTHIAZOLES | KNOPP NEUROSCIENCES, INC. (US) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009460-A1 | COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, LPXN, CLN6 | DRD3 2332/4885DRD2 1692/4885DRD4 1460/4885 |
| US-20120253047-A1 | PROCESS FOR THE PREPARATION OF (R)-PRAMIPEXOLE | DPP4, DNPEP, PNMT | DRD3 887/4885DRD2 559/4885DRD4 195/4885 |
| US-20250195672-A1 | DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTICS TO NEURONS | GPR119, SLC2A2, SLC2A1 | DRD3 859/4885DRD2 428/4885DRD4 653/4885 |
| US-20250025448-A1 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA | PPM1A, PTPN21, GABRQ | DRD3 1803/4885DRD2 2079/4885DRD4 2003/4885 |
| US-20250295604-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | PHLPP1, PHLPP2, PLAA | DRD3 3483/4885DRD2 2284/4885DRD4 4178/4885 |
| US-20130079526-A1 | Synthesis of Chirally Purified Substituted Benzothiazole Diamines | SAT1, AADAT, DDC | DRD3 525/4885DRD2 259/4885DRD4 35/4885 |
| US-20250135012-A1 | DENDRIMER CONJUGATES OF SMALL MOLECULE BIOLOGICS FOR INTRACELLULAR DELIVERY | FCGR2A, FCGR3B, SLC11A2 | DRD3 1985/4885DRD2 1560/4885DRD4 1589/4885 |
| US-20080227985-A1 | SYNTHESIS OF CHIRALLY PURIFIED SUBSTITUTED BENZOTHIAZOLES | AADAT, BCAT2, BCAT1 | DRD3 536/4885DRD2 310/4885DRD4 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.